Topic Archives: Oxford Club

Comments

No comments.

Lichtenfeld’s “Genesis Cure” — “This single technology could wipe 4,800 incurable diseases off the face of the Earth”

Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to […]

What’s the “Fingerprint of Life” Machine that (Oxford Says) can Generate 500% Short Term Gains?

[ed. note: We’re getting questions about this ad, so perhaps it’s circulating again — to help answer those questions, we’re re-posting this article that we originally published last November when we saw the first version of this ad. The Irregulars Quick Take has been updated above, but what follows has not been updated, changed or […]

Oxford’s “2016 Scientific ‘Breakthrough of the Year'” — what’s their “easiest grand-slam stock of the new year?”

I’ve been puttering around and thinking about several different teaser ads recently, but this one percolated to the top of the pile when I read Alexander Green’s characterization of it as the “Easiest Grand-Slam Stock of the New Year” … so what is it? Well, the ad is for the basic membership in the Oxford […]

“Stop What You’re Doing and Buy These Four Stocks” — What’s Fessler’s “Most Profitable Trade of My Lifetime”

Dave Fessler has an attention-getting pitch circulating right now that compares this opportunity to Halley’s Comet — a profitable trade that has “only appeared twice in the last 85 years.” The idea grabs you, naturally — it is designed to. The whole intro is about what it’s like to miss a rare opportunity, and about […]

“Black Sky Days: Capture Quick, Explosive Gains From the $3.6 Trillion Push to ‘Save the Grid'”

The relatively new “Black Sky Days” spiel from David Fessler for the Oxford Club’s Oxford Resource Explorer is getting a fair amount of attention,and it’s a very long and involved pitch that is mostly about the fact that our electric grid is old, rickety and not well-protected… and that sells us on some ways to […]

“Biotech Scientists Discover ‘Magic’ Keys to Immortality” (“Dr. Allen’s … RNA Interference Revolution: Your Ticket to Centuries of Health and Wealth”)

[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive … now they’re touting it as the holder of the “Magic” Keys to Immortality, but the […]

“This small niche player has a ‘first mover’ advantage on the complete cure for a disease that’s deadlier than cancer”

I haven’t been doing a lot with my personal portfolio over the past month — sometimes, even when the market makes you feel twitchy, I do manage to stick to the adage that has most often provided good guidance to my finances over the years: “Don’t just do something, sit there!” Sure, there are plenty […]

“How to Get Rich From the Cures on Demand Windfall” With Marc Lichtenfeld’s “Biggest Blockbuster of 2013”

Every biotech-related teaser ad promises that you can make life-changing profits while also curing the world of a dread disease, of course — that’s why we love ’em. But this one’s a little bit different — they are teasing a biotech company that is trying to develop new drugs, but according to the pitch this […]

“How Steve Jobs’ Mentor Turned a $5-Million Pipe Dream into a $340-Billion Reality”

This one may not be entirely loaded with secret stocks, since I suspect quite a few ardent Gumshoe readers have already figured out who they’re talking about as “Steve Jobs’ Mentor” … and therefore figured out which company they’re teasing … but, well, I’m still getting a lot of questions every day on this one, […]

“Starting On November 1, this ‘Can’t Lose’ Tech Stock Will Crash and Burn”

I always like to write about a bear case on a stock, or a put-buying or short-selling teaser, because they’re so rare — most people wouldn’t consider shorting stocks because of the different risk profile and the unfamiliar process, and many folks even think there’s something vaguely un-American about betting against a stock. And, of […]

Access Group (defunct)

Healthcare-focused newsletter, recommended stocks primarily of emerging device and biotech companies. Was helmed by Marc Lichtenfeld, who moved on to other publications, but stopped publishing after a short while — Lightning Trend Trader, a current publication of Lichtenfeld’s with The Oxford Club, sometimes covers biotech stocks.

“The Secret of White Caps: A Sure-Fire System to Profit Before Wall Street Even Has a Clue”

Does calling something an “index” automatically make it sound safe? That seems to be part of the premise for the recent swath of ads from the Oxford Club for what they’re calling their “Recession-Proof White Cap Index.” The ad, from Louis Basenese, is about a new investment newsletter service that they’re calling the White Cap […]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.